AdenosineThird Party Manufacturing in India

Adenosine is an endogenous purine nucleoside that acts as a potent antiarrhythmic agent by activating specific G-protein-coupled purinergic receptors (primarily A1 and A2) in cardiac tissues. When administered as a rapid intravenous bolus, adenosine binds to A1 receptors on the extracellular surface of cardiomyocytes in the sinoatrial (SA) and atrioventricular (AV) nodes. This binding inhibits adenylate cyclase, resulting in decreased cyclic adenosine monophosphate (cAMP) levels. Furthermore, A1 receptor activation directly stimulates acetylcholine-sensitive potassium channels (IKACh), causing an efflux of potassium ions and hyperpolarization of the nodal cell membrane. This hyperpolarization, coupled with the inhibition of slow inward L-type calcium currents, slows conduction time through the AV node and interrupts re-entrant pathways that involve the AV node. Adenosine has an exceptionally rapid onset and a half-life of less than 10 seconds due to its rapid uptake by erythrocytes and vascular endothelial cells, where it is metabolized to inosine or adenosine monophosphate.

Therapeutic Uses

Adenosine injection is a critical cardiac emergency medication indicated for:

• Paroxysmal Supraventricular Tachycardia (PSVT): Used for the rapid conversion of PSVT (including PSVT associated with accessory bypass tracts, such as Wolff-Parkinson-White syndrome) to normal sinus rhythm.
• Diagnostic Aid: Utilized in myocardial perfusion scintigraphy (cardiac stress testing) to induce coronary vasodilation in patients who cannot undergo exercise stress testing.
• Differential Diagnosis: Helps identify or differentiate broad-complex or narrow-complex supraventricular tachycardias in clinical settings.

Why Manufacturers Choose Adenosine

Adenosine is a life-saving emergency medicine listed on the WHO Model List of Essential Medicines. Due to its short half-life and critical emergency applications, it is formulated exclusively as a sterile, non-pyrogenic solution for intravenous injection (3mg/ml, usually in 2ml or 4ml vials).

For third-party manufacturing, adenosine represents a specialized, high-intent product segment. It is primarily procured by hospitals, cardiac care centers, emergency response teams, and government healthcare departments. Indian manufacturers with state-of-the-art sterile ampoule/vial filling lines can supply high-quality adenosine injections to both domestic distributors and international export markets. Since it is an essential drug in every emergency cart, demand remains exceptionally stable.

This makes Adenosine one of the most sought-after cardiac molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.